Clinical Trials
3 trialsNCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT03734692 2026-02-12
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT04379518 2026-01-13
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Roswell Park Cancer Institute
Phase 1/2 Terminated